• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

仑伐替尼治疗后肝细胞癌破裂：尸检病例报告。

Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report.

机构信息

Department of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Japan.

Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Japan.

出版信息

Intern Med. 2023 Apr 1;62(7):995-998. doi: 10.2169/internalmedicine.0114-22. Epub 2022 Aug 30.

DOI:10.2169/internalmedicine.0114-22
PMID:36047124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10125806/
Abstract

Hepatocellular carcinoma (HCC) hemorrhaging/rupture is a rare adverse effect of lenvatinib, and only limited pathological examinations have been reported. This report presents the case of a 69-year-old man who suffered from cardiac arrest and died 7 days after starting lenvatinib treatment for HCC, with an autopsy subsequently performed. Crack and coagulated blood were observed in the largest tumor. Pathologically, the hemorrhaging area was scattered in nearly all of the HCC lesions, regardless of tumor differentiation. This pathological feature is unusual in normal HCC. Thus, it is believed to have been the effect of lenvatinib.

摘要

肝细胞癌 (HCC) 出血/破裂是仑伐替尼的一种罕见不良反应，仅有限的病理检查报告过。本报告介绍了一例 69 岁男性患者，在开始仑伐替尼治疗 HCC 后 7 天发生心脏骤停并死亡，随后进行了尸检。最大肿瘤中观察到有裂和凝血。病理上，出血区域几乎散在于所有 HCC 病变中，无论肿瘤分化如何。这种病理特征在正常 HCC 中不常见。因此，认为这是仑伐替尼的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6e9/10125806/02e48aeaeb9f/1349-7235-62-0995-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6e9/10125806/06020a5c3203/1349-7235-62-0995-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6e9/10125806/ea2aa79a8717/1349-7235-62-0995-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6e9/10125806/a7bc04807604/1349-7235-62-0995-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6e9/10125806/71b7052597d5/1349-7235-62-0995-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6e9/10125806/02e48aeaeb9f/1349-7235-62-0995-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6e9/10125806/06020a5c3203/1349-7235-62-0995-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6e9/10125806/ea2aa79a8717/1349-7235-62-0995-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6e9/10125806/a7bc04807604/1349-7235-62-0995-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6e9/10125806/71b7052597d5/1349-7235-62-0995-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6e9/10125806/02e48aeaeb9f/1349-7235-62-0995-g005.jpg

相似文献

1
Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report.仑伐替尼治疗后肝细胞癌破裂：尸检病例报告。
Intern Med. 2023 Apr 1;62(7):995-998. doi: 10.2169/internalmedicine.0114-22. Epub 2022 Aug 30.
2
Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib.仑伐替尼起始化疗后不久导致肝癌破裂引起的腹腔内出血两例。
Intern Med. 2022 Aug 1;61(15):2301-2305. doi: 10.2169/internalmedicine.8733-21. Epub 2022 Mar 12.
3
A spontaneous rupture of lung metastasis from hepatocellular carcinoma after the introduction of lenvatinib.乐伐替尼治疗后肝细胞癌肺转移灶自发性破裂。
J Gastrointestin Liver Dis. 2021 Mar 13;30(1):169-170. doi: 10.15403/jgld-3025.
4
Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.仑伐替尼致不可切除肝细胞癌患者甲状腺功能异常。
Endocr J. 2019 Sep 28;66(9):787-792. doi: 10.1507/endocrj.EJ19-0140. Epub 2019 May 30.
5
Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.一名接受乐伐替尼治疗的肝细胞癌患者胆囊反复穿孔
Intern Med. 2020 Mar 1;59(5):657-662. doi: 10.2169/internalmedicine.3806-19. Epub 2019 Nov 18.
6
Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.乐伐替尼诱发的肝细胞癌患者间质性肺炎
Intern Med. 2022 Apr 15;61(8):1211-1217. doi: 10.2169/internalmedicine.7300-21. Epub 2021 Sep 18.
7
Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.仑伐替尼治疗活体肝移植后复发性肝细胞癌的疗效和安全性：两例报告。
Anticancer Res. 2022 Feb;42(2):1161-1167. doi: 10.21873/anticanres.15581.
8
Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.在瑞戈非尼治疗期间怀疑发生间质性肺炎，并因随后使用乐伐替尼治疗不可切除肝细胞癌而加重。
Clin J Gastroenterol. 2019 Aug;12(4):355-360. doi: 10.1007/s12328-019-00983-x. Epub 2019 Apr 24.
9
Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.乐伐替尼致晚期肝细胞癌患者结肠炎。
Clin J Gastroenterol. 2021 Feb;14(1):187-192. doi: 10.1007/s12328-020-01249-7. Epub 2020 Oct 6.
10
[A Case of Advanced Hepatocellular Carcinoma That Caused Rapid Re-Growth Due to Lenvatinib Withdrawal].[一例因停用乐伐替尼导致快速复发的晚期肝细胞癌病例]
Gan To Kagaku Ryoho. 2021 Dec;48(13):1586-1588.

引用本文的文献

1
Tumor Rupture in a Patient with Recurrent Hepatocellular Carcinoma Following Atezolizumab plus Bevacizumab: A Case Report.阿替利珠单抗联合贝伐单抗治疗后复发性肝细胞癌患者的肿瘤破裂：一例报告
Surg Case Rep. 2025;11(1). doi: 10.70352/scrj.cr.25-0331. Epub 2025 Jul 17.

本文引用的文献

1
A spontaneous rupture of lung metastasis from hepatocellular carcinoma after the introduction of lenvatinib.乐伐替尼治疗后肝细胞癌肺转移灶自发性破裂。
J Gastrointestin Liver Dis. 2021 Mar 13;30(1):169-170. doi: 10.15403/jgld-3025.
2
Development and validation of risk score for predicting spontaneous rupture of hepatocellular carcinoma.预测肝细胞癌自发破裂风险评分的开发与验证
Ann Surg Treat Res. 2020 Nov;99(5):268-274. doi: 10.4174/astr.2020.99.5.268. Epub 2020 Oct 28.
3
Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas.
仑伐替尼致大肝癌患者肿瘤相关出血
Oncology. 2021;99(3):186-191. doi: 10.1159/000510911. Epub 2020 Oct 8.
4
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.中期肝细胞癌治疗模式的转变：亚太地区原发性肝癌专家共识声明
Liver Cancer. 2020 Jun;9(3):245-260. doi: 10.1159/000507370. Epub 2020 May 13.
5
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting.在真实世界中，乐伐替尼治疗晚期肝细胞癌患者的早期反应和安全性。
JGH Open. 2019 Jun 10;4(1):54-60. doi: 10.1002/jgh3.12209. eCollection 2020 Feb.
6
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.随机、多中心前瞻性试验：比较经动脉化疗栓塞（TACE）联合索拉非尼与单纯 TACE 治疗肝细胞癌患者的疗效：TACTICS 试验。
Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4.
7
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
8
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
9
Management of hepatocellular carcinoma: an update.肝细胞癌的管理：最新进展
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
10
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition.血管生成抑制毒性中可能涉及的分子机制。
Nat Rev Cancer. 2007 Jun;7(6):475-85. doi: 10.1038/nrc2152.